Form 4: Neuronetics Director Robert Cascella Receives RSU Grant

Director Robert Cascella was granted 36,250 restricted stock units by Neuronetics, Inc. as part of his compensation.

Summary

• Director Robert Cascella acquired 36,250 restricted stock units (RSUs) on May 28, 2026.
• The RSUs were granted at a price of $0 per unit, representing a contingent right to receive one share of common stock per unit.
• Following this transaction, the director's total beneficial ownership of common stock increased to 625,017 shares.
• The award is subject to a vesting schedule tied to the earlier of May 28, 2027, or the director's separation of service or a change in control.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• The grant aligns the director's interests with those of shareholders through equity-based compensation.
• The director maintains a significant ownership stake of 625,017 shares in the company.

Negatives

• The issuance of additional RSUs results in potential future dilution for existing shareholders upon vesting.

Risks

• Vesting is contingent upon continuous service, which could be impacted by unforeseen changes in board composition or company leadership.

Future Outlook

The RSU award is expected to vest on May 28, 2027, provided the director remains in continuous service, or earlier in the event of a change in control or board-approved separation.

Management Comments

• Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the medical device and biotechnology sectors to ensure long-term alignment between governance and shareholder value.

Comparison to Industry Standards

• The use of RSU-based compensation for non-employee directors is consistent with standard corporate governance practices for mid-cap healthcare companies.
• The vesting period of one year is a common retention mechanism for board members in the industry.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual vesting and settlement of these RSUs.

Next Steps

• Vesting of the RSU award on May 28, 2027.

Key Dates

Keywords

Neuronetics, STIM, Form 4, Insider Trading, Director Compensation, Restricted Stock Units